Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0124
NEWS & VIEWS
|
Challenges and expectations for novel biologics discovery in HER2-negative breast cancer
|
|
Affiliation: Professor Franco Roviello, Via A. De Gasperi, 5-53100 Siena, Italy
E-mail : roviello@unisi.it
|
ABSTRACT
Since there is no abstract available we provide the first paragraph .
Approximately half a century after the discovery of the human epidermal growth factor (hEG F) and its receptor type 2 (HER2), biologically targeted agents such as trastuzumab and lapatinib may improve oncological outcomes of breast cancer patients whose tumors cancer cells overexpress HER2. The HER2 status has been a standard prognostic factor and patients with breast cancer are classified into HER2-negative and HER2-positive disease. Although prognosis of patients with HER2-positive cancer, as compared to HER2-negative is poorer, the addition of the monoclonal antibody trastuzumab or the tyrosine kinase inhibitor small molecule lapatinib may alter this poor outcome [1-4].
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
